[go: up one dir, main page]

NO996518D0 - Sertralinsalter og doseringsformer av sertralin med vedvarende frigjoering - Google Patents

Sertralinsalter og doseringsformer av sertralin med vedvarende frigjoering

Info

Publication number
NO996518D0
NO996518D0 NO996518A NO996518A NO996518D0 NO 996518 D0 NO996518 D0 NO 996518D0 NO 996518 A NO996518 A NO 996518A NO 996518 A NO996518 A NO 996518A NO 996518 D0 NO996518 D0 NO 996518D0
Authority
NO
Norway
Prior art keywords
sertraline
dosage forms
sustained
release
salts
Prior art date
Application number
NO996518A
Other languages
English (en)
Other versions
NO996518L (no
Inventor
Mary Tanya Am Ende
William John Curatolo
Hylar Lewis Friedman
Ravi Mysore Shanker
Scott Max Herbig
Dwayne Thomas Friesen
James Blair West
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO996518D0 publication Critical patent/NO996518D0/no
Publication of NO996518L publication Critical patent/NO996518L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO996518A 1997-07-01 1999-12-28 Sertralinsalter og doseringsformer av sertralin med vedvarende frigjøring NO996518L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5149897P 1997-07-01 1997-07-01
US5142097P 1997-07-01 1997-07-01
US5141497P 1997-07-01 1997-07-01
US5140297P 1997-07-01 1997-07-01
PCT/IB1998/000934 WO1999001121A1 (en) 1997-07-01 1998-06-15 Sertraline salts and sustained-release dosage forms of sertraline

Publications (2)

Publication Number Publication Date
NO996518D0 true NO996518D0 (no) 1999-12-28
NO996518L NO996518L (no) 2000-02-29

Family

ID=27489408

Family Applications (1)

Application Number Title Priority Date Filing Date
NO996518A NO996518L (no) 1997-07-01 1999-12-28 Sertralinsalter og doseringsformer av sertralin med vedvarende frigjøring

Country Status (32)

Country Link
US (1) US6517866B1 (no)
EP (1) EP0999830A1 (no)
JP (1) JP2000514101A (no)
KR (2) KR100412327B1 (no)
CN (1) CN1256085C (no)
AP (1) AP1526A (no)
AR (2) AR015919A1 (no)
AU (1) AU739261B2 (no)
BG (1) BG103915A (no)
BR (1) BR9810403A (no)
CA (1) CA2290966C (no)
CO (1) CO4940402A1 (no)
DZ (1) DZ2546A1 (no)
EA (1) EA002482B1 (no)
HR (1) HRP980379B1 (no)
HU (1) HUP0002296A3 (no)
ID (1) ID23503A (no)
IL (2) IL133080A0 (no)
IS (1) IS5265A (no)
MY (1) MY129175A (no)
NO (1) NO996518L (no)
NZ (2) NZ513456A (no)
OA (1) OA11245A (no)
PA (1) PA8454401A1 (no)
PE (1) PE88699A1 (no)
PL (1) PL337806A1 (no)
SK (1) SK180499A3 (no)
TN (1) TNSN98125A1 (no)
TR (1) TR199903280T2 (no)
TW (1) TWI241188B (no)
UY (1) UY25067A1 (no)
WO (1) WO1999001121A1 (no)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208926A1 (en) * 1997-07-01 2004-10-21 Pfizer Inc Solubilized sertraline compositions
JP4533531B2 (ja) * 1998-04-03 2010-09-01 ビーエム リサーチ エイ／エス 制御放出組成物
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
SK286865B6 (sk) * 1999-05-20 2009-06-05 Elan Pharma International Limited Multičasticový farmaceutický prostriedok s riadeným uvoľňovaním selektívneho inhibítora spätného príjmu serotonínu a jeho použitie
DE60026146T2 (de) * 1999-09-03 2006-08-17 Apbi Holdings, Llc Verwendung von Dapoxetin, A selektiver Serotonin Aufnahme Inhibitor mit schnellem Wirkungseintritt, zur Behandlung von sexueller Disfunktion
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
WO2001047498A2 (en) 1999-12-23 2001-07-05 Pfizer Products Inc. Hydrogel-driven layered drug dosage form comprising sertraline
US6620431B1 (en) * 2000-04-17 2003-09-16 Charles Signorino Shellac film coatings providing release at selected pH and method
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
CA2420535A1 (en) 2000-08-30 2002-03-07 Mary Tanya Am Ende Sustained release formulations for growth hormone secretagogues
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
SE0004671D0 (sv) 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
JP2002212062A (ja) * 2001-01-24 2002-07-31 Teijin Ltd 遅延放出制御組成物
JPWO2002064114A1 (ja) * 2001-02-15 2004-06-10 株式会社三和化学研究所 新規眼科用組成物
AU2002248792B2 (en) * 2001-04-18 2006-09-21 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
HUP0401941A3 (en) * 2001-07-16 2008-04-28 Astrazeneca Ab Pharmaceutical formulation comprising a proton pomp inhibitor and antacids and process for its preparation
EP2957281A1 (en) 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
CA2461653A1 (en) * 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Edible composition and dosage form comprising an edible shell
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US20100189797A1 (en) 2002-06-10 2010-07-29 Julien Mendlewicz Oral antidepressant formulation
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US20040087661A1 (en) * 2002-09-16 2004-05-06 Sepracor, Inc. Treatment of CNS disorders with trans 4-3(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
CA2415154C (en) * 2002-12-24 2009-06-16 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors
WO2004065348A1 (en) 2003-01-23 2004-08-05 Pfizer Products Inc. Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof
WO2004073614A2 (en) * 2003-02-14 2004-09-02 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders
ES2360102T3 (es) * 2003-03-26 2011-05-31 Egalet A/S Sistema para la liberación controlada de morfina.
CA2520321A1 (en) * 2003-04-04 2004-10-14 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
JP4790597B2 (ja) 2003-04-24 2011-10-12 ヤゴテック アーゲー 規定されたコア幾何学的配置を有する遅延放出錠
US7186863B2 (en) 2003-05-23 2007-03-06 Transform Pharmaceuticals, Inc. Sertraline compositions
EP1575565B1 (en) * 2003-08-08 2010-01-06 Biovail Laboratories International Srl Modified-release tablet of bupropion hydrochloride
US7893300B2 (en) * 2003-11-04 2011-02-22 Cipla Limited Process for the preparation of polymorphs of selective serotonin reuptake inhibitor
AR048033A1 (es) * 2004-03-12 2006-03-22 Smithkline Beecham Plc Composicion farmaceutica para moldear componentes que comprende copolimero de poli(met)acrilato, cubierta, conector o espaciador de capsula moldeado por inyeccion que tiene la composicion farmaceutica y forma de dosificacion farmaceutica de multicomponentes a partir de dicha composicion
KR100772980B1 (ko) * 2004-04-01 2007-11-02 한미약품 주식회사 메트포르민의 경구투여용 서방성 제제
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
ITMI20041295A1 (it) * 2004-06-25 2004-09-25 Cosmo Spa Composizioni farmaceutiche antimicrobiche orali
RS52057B2 (sr) 2004-08-13 2018-03-30 Boehringer Ingelheim Int Formulacija tablete sa produženim oslobađanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so
KR100920856B1 (ko) * 2004-11-30 2009-10-09 (주)아모레퍼시픽 선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법
WO2006072878A1 (en) * 2005-01-07 2006-07-13 Ranbaxy Laboratories Limited Oral dosage forms of sertraline having controlled particle size and processes for their preparation
US20080274183A1 (en) * 2005-02-04 2008-11-06 Phillip Michael Cook Thermoplastic articles containing a medicament
EP1858493A4 (en) * 2005-03-14 2010-12-01 Sun Pharmaceutical Ind Ltd SYSTEM FOR ORAL ADMINISTRATION OF MEDICINAL PRODUCTS
WO2006128471A2 (en) * 2005-06-03 2006-12-07 Egalet A/S A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
US8747897B2 (en) * 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
US7893053B2 (en) * 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
EP2049123B2 (en) 2006-08-03 2016-08-24 Horizon Pharma AG Delayed-release glucocorticoid treatment of rheumatoid disease
EP2104493A2 (en) * 2007-01-16 2009-09-30 Egalet A/S Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
NZ592765A (en) * 2008-08-14 2013-06-28 Bioneer As Tablets with a coating which impedes the release of an active ingredient
DE102008051572A1 (de) 2008-09-05 2010-03-11 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Herstellung von Phosphatbindern und auf diese Weise hergestellte Phosphatbinder
AU2008243202B2 (en) * 2008-11-11 2015-08-20 Cosmo Technologies Ltd Oral antimicrobial pharmaceutical compositions
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
EP2498764B1 (en) 2009-11-09 2017-09-06 Spotlight Technology Partners LLC Fragmented hydrogels
NZ599524A (en) 2009-11-09 2014-04-30 Spotlight Technology Partners Llc Polysaccharide based hydrogels
AU2013285988A1 (en) 2012-07-06 2015-02-12 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
WO2016020936A2 (en) * 2014-07-21 2016-02-11 Patel Jayendrakumar Dasharathlal A novel oral gastroretentive pharmaceutical dosage form
CN104402705B (zh) * 2014-11-04 2017-04-12 成都理工大学 球形柠檬酸钙及其制备方法和应用
JP6455293B2 (ja) * 2015-04-21 2019-01-23 ニプロ株式会社 セルトラリン及び／又はその薬学上許容しうる塩を含む製剤
US20200009076A1 (en) * 2017-03-08 2020-01-09 Cinrx Pharma, Llc Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
JP7184451B2 (ja) * 2017-10-05 2022-12-06 ピュラック バイオケム ビー． ブイ． 乳酸塩粉末及びその調製方法
CN109432038A (zh) * 2018-12-28 2019-03-08 乐普制药科技有限公司 一种含有盐酸舍曲林的肠溶片剂及其制备方法
GB201914779D0 (en) * 2019-10-11 2019-11-27 Oxford Medical Products Ltd Polymer compositions
EP4311113A1 (en) 2022-07-21 2024-01-24 Rohde & Schwarz GmbH & Co. KG Radio frequency receiver and operation method thereof
CN118522388B (zh) * 2024-07-25 2024-10-11 北京科技大学 二元复配有机缓蚀剂优化方法、装置、设备及介质
CN119915068B (zh) * 2025-04-01 2025-07-08 烟台华孚制冷设备有限公司 一种盘式制冷装置及冰淇淋机

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US5112619A (en) 1985-11-12 1992-05-12 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulation
US4797286A (en) 1985-11-12 1989-01-10 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
US4847092A (en) 1985-11-12 1989-07-11 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
DE3700420A1 (de) 1986-12-22 1988-07-07 Efka Werke Kiehn Gmbh Fritz Tabakerzeugnis fuer die selbstverfertigung einer zigarette, insbesondere filter-zigarette
US5135947A (en) 1987-04-09 1992-08-04 Eli Lilly And Company 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
US4839104A (en) 1987-06-11 1989-06-13 Pfizer, Inc. Process for preparing sertraline intermediates
US4792448A (en) 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
US4777288A (en) 1987-06-11 1988-10-11 Pfizer Inc. Process for preparing a 4,4-diphenylbutanoic acid derivative
US4971998A (en) 1987-10-22 1990-11-20 Massachusetts Institute Of Technology Methods for treating the premenstrual or late luteal phase syndrome
US4876282A (en) 1987-11-25 1989-10-24 Eli Lilly And Company 1-Phenylalkylamines as selective serotonin uptake inhibitors
US4855500A (en) 1988-05-04 1989-08-08 Pfizer Inc. Process for preparing a ketimine
US5026707A (en) 1988-05-23 1991-06-25 Eli Lilly And Company Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
IL91398A (en) * 1988-08-30 1994-05-30 Pfizer Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane
IL114715A (en) 1989-02-27 1997-01-10 Lilly Co Eli Intermediate compounds for ring-substituted 2-amino-1, 2, 3, 4-tetrahydronaphthalenes and 3-aminochromanes
US4981870A (en) 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US4983401A (en) 1989-05-22 1991-01-08 Kinaform Technology, Inc. Sustained release pharmaceutical preparations having pH controlled membrane coatings
US4940731A (en) 1989-08-30 1990-07-10 Pfizer Inc. Method of treating premature ejaculation using sertraline
US5130338A (en) 1989-08-30 1992-07-14 Pfizer Inc. Method of treating chemical dependencies using sertraline
EP0415612B1 (en) 1989-08-30 1993-11-10 Pfizer Inc. Use of sertraline for the treatment of chemical dependencies
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
WO1992000103A1 (en) 1990-06-28 1992-01-09 Beecham Group Plc Pharmaceutical preparations
DE69107461T2 (de) 1990-08-07 1995-06-22 Pfizer Verwendung von interfacial polymerisierten membranen in abgabevorrichtungen.
AU8629691A (en) 1990-08-09 1992-03-02 Massachusetts Institute Of Technology Method for treating the premenstrual or late luteal phase syndrome
US5104899A (en) 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
EP0558679A1 (en) 1990-11-24 1993-09-08 BEECHAM GROUP plc Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
ATE197145T1 (de) 1991-02-08 2000-11-15 Lilly Co Eli Ringsubstituierte 2-amino-1,2,3,4- tetrahydronaphtahline und 3-aminochromane
AU1919592A (en) 1991-04-16 1992-11-17 National Institutes Of Health Method of treating trichotillomania and onychophagia
US5196607A (en) 1992-02-14 1993-03-23 Pfizer Inc. Process for preparing ketone enantiomer
ATE173159T1 (de) 1992-03-25 1998-11-15 Depomed Systems Inc Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
IE930485A1 (en) 1993-06-28 1994-12-28 Hemisphere Ltd Antidepressant agents with a rapid onset of action
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
DE69525847T2 (de) 1994-09-19 2002-09-05 Dupont Pharmaceuticals Co., Wilmington Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit
DE69626916T2 (de) 1995-07-17 2003-10-09 Pfizer Inc., New York Sertralin zur Behandlung von Post-Myocard-Infarkt-Patienten
GB9514842D0 (en) 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
PL187926B1 (pl) 1996-03-25 2004-11-30 Lilly Co Eli Kompozycja farmaceutyczna do leczenia bólu
ZA97976B (en) 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.
US5741807A (en) 1996-09-27 1998-04-21 Cytos Pharmaceuticals, L.P. Histidine compositions and methods for treating or preventing infectious and non-infectious diarrheas
US6590083B1 (en) 1999-04-16 2003-07-08 Ortho-Mcneil Pharmaceutical, Inc. Ketolide antibacterials

Also Published As

Publication number Publication date
JP2000514101A (ja) 2000-10-24
KR20040004367A (ko) 2004-01-13
BR9810403A (pt) 2000-08-29
MY129175A (en) 2007-03-30
CN1261793A (zh) 2000-08-02
AU739261B2 (en) 2001-10-11
HRP980379B1 (en) 2003-04-30
WO1999001121A1 (en) 1999-01-14
BG103915A (en) 2000-07-31
PL337806A1 (en) 2000-09-11
OA11245A (en) 2003-07-23
IS5265A (is) 1999-11-23
NZ501251A (en) 2001-09-28
PE88699A1 (es) 1999-09-20
CN1256085C (zh) 2006-05-17
KR100446366B1 (ko) 2004-09-01
HRP980379A2 (en) 1999-04-30
DZ2546A1 (fr) 2003-02-08
IL152330A0 (en) 2003-05-29
EA002482B1 (ru) 2002-06-27
UY25067A1 (es) 2000-12-29
HK1026630A1 (en) 2000-12-22
AU7544998A (en) 1999-01-25
TWI241188B (en) 2005-10-11
EP0999830A1 (en) 2000-05-17
IL133080A0 (en) 2001-03-19
AP9801281A0 (en) 1998-06-30
KR100412327B1 (ko) 2003-12-31
CA2290966A1 (en) 1999-01-14
AR015919A1 (es) 2001-05-30
PA8454401A1 (es) 2000-05-24
SK180499A3 (en) 2001-08-06
NZ513456A (en) 2003-02-28
NO996518L (no) 2000-02-29
CO4940402A1 (es) 2000-07-24
TR199903280T2 (xx) 2000-11-21
KR20010014043A (ko) 2001-02-26
HUP0002296A3 (en) 2001-11-28
AR065827A2 (es) 2009-07-08
US6517866B1 (en) 2003-02-11
EA199900964A1 (ru) 2000-08-28
AP1526A (en) 2006-01-03
CA2290966C (en) 2005-12-20
HUP0002296A2 (hu) 2001-10-28
TNSN98125A1 (fr) 2005-03-15
ID23503A (id) 2000-04-27

Similar Documents

Publication Publication Date Title
NO996518D0 (no) Sertralinsalter og doseringsformer av sertralin med vedvarende frigjoering
TW350844B (en) Tricyclic amides useful to inhibition of G-protein function and for treatment of proliferative diseases
DK0841928T3 (da) Sustained release-formulering af d-threo-methylphenidat
AR038434A2 (es) Compuesto 14,15-dihidro-16-oxoparahercuamida y compuestos 2-desoxo de parahercuamida y marcfortina
SG80530A1 (en) Pharmaceutical combination for the treatment of prostatic hyperplasia, containing a 5 alpha-reductase inhibitor and an antiandrogen
CY1108348T1 (el) Υποκατεστημενα 2-(2,6-διοξοπιπεριδιν-3-υλ)-φθαλιμιδια και μεθοδος μειωσης των tnf αλφα επιπεδων
ITTO940819A0 (it) "piastra di ancoraggio"
FI923497A0 (fi) Roterande anslutning med laonglivad taetning.
NO996287D0 (no) Chalkoner med antiproliferativ aktivitet
NO996519L (no) Doseringsformer av sertralin med forsinket frigjøring
BG105651A (en) Vitronectin receptor antagonist
NO20001548L (no) Endotelinantagonist og en renin-angiotensinsystem inhibitor som et kombinert preparat
SE9302218D0 (sv) New use
PL326294A1 (en) Method of retarding the inhibitor 1 of plasminogene activator
ITMI910253A1 (it) Associazione farmaceutica per la prevenzione e il trattamento dell'osteoporosi post-menopausale
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
SE9404438D0 (sv) New process
SE9501773D0 (sv) New use
ZA985707B (en) Sertraline salts and sustained-release dosage forms of sertraline.
FR2657005B1 (fr) Systeme d'enclouage pour le traitement des fractures notamment du type cervico-trochanteriennes et pertrochanteriennes.
FR2752737B1 (fr) Comprime a liberation controlee de chlorhydrate d'alfuzosine
IT1288184B1 (it) Procedimento per l'accorciamento del tempo di chiusura e dispositivo per l'attuazione del procedimento.
ITBZ950016A0 (it) Impianto odontoiatrico complementare,procedimento per la sua attuazione ed elemento di sostegno facente parte dell'impianto.
KR970019262U (ko) 사용경과시간을 알리는 컴퓨터
PL312100A1 (en) Agent acting highly plasticisingly on and retarding the setting of concrete

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application